Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy.

Dermatol Ther (Heidelb) · 2025 · PMC11909319 · PMID 39953372

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Although lebrikizumab was comparable to dupilumab on all measured outcomes at week 16, it showed a trend toward better odds for itch improvement than dupilumab at weeks 4 and 16.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.